Get the Stockscreener App
7.90
3.42%
-0.28
Capricor Therapeutics Inc stock is traded at $7.90, with a volume of 1.79M.
It is down -3.42% in the last 24 hours and down -18.56% over the past month.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
See More
Previous Close:
$8.18
Open:
$7.93
24h Volume:
1.79M
Relative Volume:
0.60
Market Cap:
$360.85M
Revenue:
$27.10M
Net Income/Loss:
$-24.31M
P/E Ratio:
-9.5181
EPS:
-0.83
Net Cash Flow:
$-33.33M
1W Performance:
+11.90%
1M Performance:
-18.56%
6M Performance:
-47.47%
1Y Performance:
+102.05%
1-Day Range:
$7.72
$8.28
1-Week Range:
$6.61
$8.55
52-Week Range:
$3.52
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Compare CAPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
7.90 | 373.89M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Initiated | Alliance Global Partners | Buy |
| Jun-26-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | Roth Capital | Buy |
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
Does Capricor Therapeutics Inc. stock perform well during market downturnsBest Dividend Tips From AI Tools - jammulinksnews.com
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ACCESS Newswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - GlobeNewswire
September 15, 2025 Deadline: Join Class Action Lawsuit Against Capricor Therapeutics, Inc. (CAPR)Contact Levi & Korsinsky - Newsfile
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - FinancialContent
When is Capricor Therapeutics Inc. stock expected to show significant growthBreakout Stocks Opportunities That Work - jammulinksnews.com
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Capricor - GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CAPR - GlobeNewswire Inc.
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - PR Newswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. LawsuitCAPR - PR Newswire
Will Capricor Therapeutics Inc. bounce back from current supportReal Trader Watchlist with Entry Targets - Newser
Analyzing Capricor Therapeutics Inc. with risk reward ratio chartsExit Strategy Guide With Risk Control Plan - Newser
How to manage a losing position in Capricor Therapeutics Inc.AI Driven Swing Trade Forecasting Insight - Newser
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
Replimune, Sarepta, Capricor Stocks Surge: Analyst Says Vinay Prasad’s Exit From FDA Positive For Biopharma Sector - Stocktwits
Robbins LLP Reminds CAPR Investors with Large Losses of the Class Action Lawsuit on Behalf of Capricor Therapeutics, Inc. Shareholders - PR Newswire
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? - Benzinga
Sarepta stock, Replimmune stock up as FDA’s biologics head exits - Seeking Alpha
Capricor Stock Soars 21.07% on Clinical Trial Success - AInvest
Shareholders that lost money on Capricor Therapeutics should contact Faruqi & Faruqi about pending Class ActionCAPR - The Malaysian Reserve
Capricor Investors Sue Over Misleading FDA Approval Claims – What You Need to Know - TradingView
Capricor Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your RightsCAPR - PR Newswire
Shareholders of Capricor Therapeutics, Inc. (CAPR): Protect Your Rights Before September 15, 2025Contact Levi & Korsinsky - TradingView
What makes Capricor Therapeutics Inc. stock price move sharplyAI Triggered Buy Zone Forecast System - Newser
Bragar Eagel & Squire, P.C. Urges Investors in XPLR - GlobeNewswire
Class Action Filed Against Capricor Therapeutics, Inc. - GlobeNewswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - Morningstar
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor ... - Bluefield Daily Telegraph
Capricor Therapeutics to Host Webinar on Deramiocel and Duchenne Muscular Dystrophy in Collaboration with Parent Project Muscular Dystrophy - Quiver Quantitative
Capricor Therapeutics and Parent Project Muscular Dystrophy - GlobeNewswire
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy - Yahoo Finance
Class Action Filed Against Capricor Therapeutics, Inc. (CAPR) Seeking Recovery for InvestorsContact The Gross Law Firm - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Relative strength of Capricor Therapeutics Inc. in sector analysisAI Entry Timing Prediction for Swing Traders - Newser
What is the risk reward ratio of investing in Capricor Therapeutics Inc. stockMaximize gains with data-driven trading alerts - jammulinksnews.com
Why is Capricor Therapeutics Inc. stock attracting strong analyst attentionGet expert insights on market-moving stocks - jammulinksnews.com
Lost Money on Capricor Therapeutics, Inc. (CAPR)? Contact Levi & Korsinsky Before September 15, 2025 to Join Class Action - ACCESS Newswire
What are analysts’ price targets for Capricor Therapeutics Inc. in the next 12 monthsBuild your wealth with consistent stock growth - jammulinksnews.com
Investors who lost money on Capricor Therapeutics, Inc. - GlobeNewswire
CAPR Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the ... - Bluefield Daily Telegraph
CAPR Class Action Alert: Robbins LLP Reminds Investors of - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire
Join Class Action to Recover Losses from Capricor Therapeutics, Inc. (CAPR)Contact Levi & Korsinsky Before September 15, 2025 - Newsfile
Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025CAPR - PR Newswire
Should I buy Capricor Therapeutics Inc. stock before earningsHigh-yield capital appreciation - jammulinksnews.com
What analysts say about Capricor Therapeutics Inc. stockUnstoppable trading performance - Autocar Professional
Is Capricor Therapeutics Inc. a good long term investmentSignificant capital appreciation - Autocar Professional
Investors who lost money on Capricor Therapeutics, - GlobeNewswire
Bragar Eagel & Squire, P.C. Urges Investors in XPLR Infrastructure, Centene, Biohaven, or Capricor to Inquire About Their Rights in Class Action Lawsuits - Morningstar
Capricor Therapeutics Inc. Stock Analysis and ForecastExtraordinary earning power - PrintWeekIndia
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):